Masimo Focus and History
Masimo (NASDAQ: MASI) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors.
Since 1989, Masimo has been focused on noninvasive patient monitoring technologies that are more effective and reliable and to improve patient outcomes.
Masimo is the inventor of measure-through motion and low perfusion pulse oximetry and Pulse CO-Oximetry technologies, and provides this technology in a number of pulse oximetry technology solutions.
Masimo is responsible for the development of:
- Masimo SET® pulse oximetry to help eliminate O2 false alarms.
- Masimo Rainbow Pulse CO-Oximetry. Introduced in 2005 as a noninvasive technology to avoid painful and time consuming invasive testing procedures.
- Masimo noninvasive and continuous total hemoglobin (SpHb™) the first-and-only FDA-cleared technology that noninvasively and continuously measures total hemoglobin without a painful needle stick and invasive blood draw.
Joe Kiani founded Masimo in 1989 as a private "garage start-up" company because he was convinced that the use of adaptive signal processing in the measurement of physiological parameters could solve the problems of low perfusion and motion, which had long plagued in-vivo monitoring and especially pulse oximetry. Today, Masimo has grown into a successful publicly-traded medical technology company employing thousands of people worldwide.
Masimo has also licensed it's technology to companies such as Atom, Datascope, GE Medical, Medtronic, Philips, Spacelabs and Zoll, among others.
In 1995, Masimo debuted measure-through motion and low perfusion pulse oximetry, known as Masimo SET that helped eliminate false alarms and increased pulse oximetry's ability to detect life-threatening events. At that time more than 100 independent and objective studies demonstrate that Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion.
In 2005, Masimo introduced Masimo Rainbow Pulse CO-Oximetry, a noninvasive blood constituent monitoring technology that measures many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®) and pleth variability index (PVI®), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), enabling early detection and treatment of potentially life-threatening conditions.